ERBB2 and breast carcinoma: Moreover, in contrast to trastuzumab, lapatinib can inhibit HER2 activation via ligand-induced heterodimerization or truncated HER2 receptors, and it has also proven effective in the treatment of PTEN-deficient breast cancer, thus illustrating the potential advantages of lapatinib over trastuzumab [7], [8].